finanzen.net
27.03.2020 02:57

The Cardiac Risk of Chloroquine in Unapproved Indications

Werbung

NEW ORLEANS, March 26, 2020 /PRNewswire/ -- The current COVID-19 pandemic has impacted economic and social aspects of society around the globe.  Recently, the unapproved use of the antimalarial drug, chloroquine, has been touted as a treatment for COVID-19 with some reported deaths with its use in afflicted patients.  Chloroquine has been used clinically for over 60 years and the side effect profile is well established.  A common and potentially life-threatening side effect is a change in the ECG and in particular to the QT interval.  The QT interval corresponds to the time period during which the heart relaxes and prolongation of the QT interval can be associated with life-threatening arrhythmias and sudden cardiac death.  Because the QT interval is influenced by heart rate, it is most often given as the corrected QT interval or QTc. 

Even therapeutic doses of chloroquine in healthy patients are associated with prolongation of QTc1, although this is generally well tolerated.  The concern with the current off-label use of chloroquine is that people with COVID-19 will self-medicate and take much more than the approved therapeutic dose used for treatment of malaria.  In fact, the WHO reported that most of the cases of life-threatening arrhythmias associated with chloroquine use occur when used to treat other indications2

In order to provide insight into the effects of various doses of chloroquine on QTc, we used our proprietary QT Fingerprinting™ model to predict the change in QTc at therapeutic doses and doses 2 to 22 times higher than therapeutic.  As seen in the plot, the predicted increase in QTc (8.8ms) was very close to the observed increase in QTc (6.1ms) at a therapeutic dose.  Doses 2-22 times higher were associated with predicted increases in QTc up to approximately 35ms.  While these increases in QTc may be well tolerated in healthy patients, the concern is for patients who have underlying cardiac disease, risk factors for QT prolongation, or are taking other drugs which prolong the QT interval.  This is why chloroquine has specific warnings in its labeling to inform of the potential danger in patients with underlying risk factors (cardiac disease, hypokalemia, hypomagnesemia, bradycardia)3. The QTc prolonging effects of chloroquine will very likely be much greater and life-threatening in patients who take more than the prescribed dose and have existing risk factors.  Caution should be exercised by government leaders and the public in assuming chloroquine is either effective in treating COVID-19 or without significant side-effects.

By: Willam J. Crumb Jr., Ph,D. Director of Scientific Operations, Nova Research Laboratories
New Orleans, LA   w.crumb@novreslab.com

1  Pukrittayakamee S et al. Pharmacokinetic Interactions between Primaquine and Chlroquine. Antimicrobial Agents and Chemotherap. 2014. 58:3354-3359.
2  WHO Evidence Review Group. The cardiotoxicity of antimalarials. 2017. http://www.who.int/malaria/mpac/mpac-mar2017-erg-cardiotoxicity-report-session2.pdf.
3  ARALEN CHLOROQUINE PHOSPHATE, USP Label – FDA, www.accessdata.fda.gov › drugsatfda_docs › label

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/the-cardiac-risk-of-chloroquine-in-unapproved-indications-301030756.html

SOURCE Nova Research Laboratories

Werbung
Werbung
Werbung
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX legt zu -- Asiens Börsen mehrheitlich fest -- SAP kappt Prognose für 2020 -- Gerresheimer bestätigt Jahresausblick -- UBS teilt Dividende auf -- Starbucks, Airbus im Fokus

Volkswagen sieht in China deutliche Zeichen für eine Erholung. Facebook führt Plattform für Hilfsangebote auch in Deutschland ein. Vergleichsportal: Weitere Geldhäuser bürden Sparern Negativzinsen auf. Diageo streicht Prognose. E.ON-Hauptversammlung soll virtuell stattfinden. Credit Suisse teilt Dividende in zwei Tranchen auf.

Die 5 beliebtesten Top-Rankings

Die Länder mit den größten Goldreserven
Wer lagert das meiste Gold?
Welche Marken sind vorne mit dabei?
BrandZ-Ranking: Das sind die wertvollsten deutschen Marken
Das sind die besten Renten-Länder
In welchen Ländern lohnt es sich, zur Ruhe zu setzen?
Rohstoffe: Die Gewinner und Verlierer in Q1 2020
Welcher Rohstoff macht das Rennen?
MDAX: Die Gewinner und Verlierer in Q1 2020
Welche Aktie macht das Rennen?
mehr Top Rankings

Umfrage

Corona-Crash an den Börsen: Wird der DAX im April noch weiter fallen?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Microsoft Corp.870747
Deutsche Bank AG514000
Wirecard AG747206
Scout24 AGA12DM8
Lufthansa AG823212
TeslaA1CX3T
Daimler AG710000
Shell (Royal Dutch Shell) (A)A0D94M
Airbus SE (ex EADS)938914
NEL ASAA0B733
Allianz840400
TUITUAG00
Apple Inc.865985
Amazon906866
Infineon AG623100